Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study

Inclusion criteria

• Patient aged 18 years or more
• Patient with histologically confirmed, localized endometrial cancer, candidate for surgical treatment.
• Patient with localized endometrial cancer, presenting:

• A high-grade endometrioid histological type and/or
• P53 mutation and/or
• a non-endometrioid histological type regardless of P53 status.
• Patient affiliated to a social security scheme
• Information and signature of informed consent prior to any specific study procedure

Exclusion criteria

• Other active cancer less than 6 months old (with the exception of treated basal cell carcinoma of the skin).
• Patient deprived of liberty, under guardianship, or subject to a legal protection measure, or unable to express consent.